

Summary of Studies Supporting USDA Product Licensure

Establishment Name	Medgene Labs
USDA Vet Biologics Establishment Number	474
Product Code	19A5.R9
True Name	Swine Influenza Vaccine, H3, Killed Baculovirus Vector
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	
Date of Compilation Summary	August 11, 2021

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

474 19A5.R9 Page 1 of 5

Study Type	Efficacy										
Pertaining to	Swine Influer	nza V	accine, I	H3, Killed	l Baculovi	rus Vecto	or				
Study Purpose	To demonstra	ate eff	icacy ag	ainst swi	ne influenz	za virus (H3)				
Product Administration	2 doses, given intramuscularly, 3 weeks apart										
Study Animals	3-4-week-old pigs, 30 vaccinates and 14 controls										
Challenge Description	Swine Influenza Virus (A/Swine/IA/A01566613/2014-H3N2)										
	was administered 14 days following 2 nd vaccination.										
Interval observed after	Pigs were eva						allenge.				
challenge	Lung lesions were evaluated at 5 days post challenge.										
Results	Lung lesion s										
	total lung lesion percentage was calculated for every animal.										
					(2.1)						
	5-number sur	nmary	y for Lui	ng Lesion	(%)		75 th Max Pctl 3.99 10.86 0.00 1.60				
	[TD	<u> </u>	3.4.	a # th	N # 10	= = th	3.6				
	Treatment	n	Min	25 th Pctl	Median		Max				
	Controls	14	0.00	0.75	2.68		10.86				
	Vaccinates	30	0.00	0.00	0.00						
	vacemates	50	0.00	0.00	0.00	0.00	1.00				
	Summary of	the Ni	umber o	f Affected	d Pigs in Each Group:						
	Treatment Positive Negative Total						Total				
	Treatment			Dogitizzo							
	liteati	ment		Positive Lesion			Total				
	liteati	ment		Lesion	Lesio	n	1 otal				
	Cont					n	14				
		rols		Lesion Score ¹	Lesio Score	n					
	Cont	rols		Lesion Score ¹ 13	Lesion Score 1	n	14				
	Cont	rols		Lesion Score ¹ 13	Lesion Score 1	n	14				
	Cont	rols		Lesion Score ¹ 13	Lesion Score 1	n	14				
	Cont	rols		Lesion Score ¹ 13	Lesion Score 1	n	14				
	Cont	rols		Lesion Score ¹ 13	Lesion Score 1	n	14				
	Cont Vaccin Lung Lesion	rols nates % >0 =	= positive, o	Lesion Score ¹ 13 6 otherwise ne	Lesion Score 1	n	14				
USDA Approval Date	Cont	rols nates % >0 =	= positive, o	Lesion Score ¹ 13 6 otherwise ne	Lesion Score 1	n	14				

474 19A5.R9 Page 2 of 5

Lung Lesion Scores (%), in order of rank:

Vaccinate	Control
0	0
0	0.2
0	0.5
0	0.75
0	0.85
0	1.15
0	1.8
0	3.55
0	3.625
0	3.8
0	3.9875
0	4.475
0	4.75
0	10.8625
0	
0	
0	
0	
0	
0	
0	
0	
0	
0	
0.05	
0.1	
0.25	
0.35	
0.7625	
1.6	

474 19A5.R9 Page 3 of 5

Study Type	Safety						
Pertaining to	•	fluenza Vac	ccine, H3	3			
Study Purpose	To demo	nstrate safe	ty under	field co	nditions		
Product		given intran				t	
Administration							
Study Animals		at 4 sites in	3 distin	ct geogr	aphical r	regions. Minii	mum age 28
CI II	days	1.1					
Challenge	Not appli	icable					
Description	NI 4 1	11					
Interval observed	Not appli	icable					
after challenge	D.	1 1	. 1.	, 1 C	1	· ,·	1 1 '1
Results		e observed i 14 days afte				accination and	a dany
		•		, , , , ,			
	Injection	Site React	tions				
	Site	Total # of Animals	Maximum Size of Injection Site Reaction (cm)			Total # of Animals with Injection	Animals with No Injection Site
			<1.5	1.5- 5.0	>5.0	Site Reactions	Reaction
	Site 1	230	26	10	0	36	194
	Site 2	217	36	1	0	37	180
	Site 3	223	123	21	0	144	79
	Site 4	229	11	2	0	13	216
		7	230	669			
	All inject	tion site rea	ctions re	solved v	within 3	weeks of vaco	cination.

474 19A5.R9 Page 4 of 5

Clinical Observation	Number of Clinical Observation Post-Vaccination			
	Site 1	Site 2	Site 3	Site
Abdominal Cavity Hernia	6	0	0	1
Bacterial Skin Infection	0	0	0	1
Cough	0	0	0	1
Cyst on Rump	0	0	0	1
Depression	1	0	0	0
Ear sore	0	0	0	3
Facial Scar	0	0	0	1
Facial Swelling	0	0	0	1
Fainting	1	0	0	0
Hair Change	2	0	0	5
Injection Site Abscess	2	0	0	0
Injection Site Reddening	5	0	0	0
Injection Site Scratching	1	0	0	0
Joint Swelling	1	0	0	0
Labored Breathing	1	0	0	0
Lameness	2	0	0	3
Anorexia	4	3	0	6
Puncture Wound	1	0	0	0
Rash (not at injection site)	0	1	0	0
Scrotal oedema	0	0	0	1
Skin Scab (not at injection				
site)	2	0	0	0
Smaller Pig	0	0	0	1
Swollen Limb	0	0	0	2
Tiredness	4	3	0	0
Unable to Stand/Ataxia	1	0	0	0
Unthrifty	1	6	0	13
Weakness	8	0	0	0
Death	0	1	0	0

USDA Approval Date 06/09/2020

474 19A5.R9 Page 5 of 5